LabGenius

EXCITING NEWS! 📣 Today we announce LabGenius’ £35 million Series B fundraise! 🎉 The round was led by M Ventures with participation from new investors Octopus Ventures, LG Corp. and Recode Ventures alongside existing investors Atomico, Kindred Capital VC, Lux Capital and Obvious Ventures. The proceeds from the round will enable us to further advance our ML-driven antibody discovery platform and progress a pipeline of multispecific antibodies for the treatment of solid tumours towards the clinic. As part of this fundraise, we welcome Oliver Hardick (M Ventures) and Oliver Sims (Octopus Ventures) to the Board. They will serve alongside current Board members Edwin Moses (Chairman), Irina Elena Haivas (Atomico) and Leila Rastegar Zegna (Kindred). 🗞️ For more details on the round, check out the press release here - https://lnkd.in/erQrPsTE 💡Our CEO, James Field, shares his personal perspective on what this financing means for LabGenius here - https://lnkd.in/eKZen4rm

Following the news of their £35M funding round, I sat down with James Field, CEO and founder of LabGenius for the latest episode of What's Next. LabGenius is on a mission to not only help find novel treatments for cancer and other illnesses, but to use AI to augment the scientific method itself. In this episode we discuss: - how he went from academic lab to CEO & founder 👨🎓 - the critical role grants, angels and investors have played 💰 - the breakthroughs in AI that have accelerated LabGenius's progress to find novel therapeutics ⚗ - how AI will augment scientists, and change the way science is done 🔬 Check it out on Youtube and your favourite podcasting platforms below:

📖 Antibody discovery and development has progressed considerably, with machine learning offering a promising way to improve the process. But challenges remain with the application of ML - often due to a lack of rigorous model training and evaluation, or bad data practices. 💡 In their latest paper, published in Drug Discovery Today, Sandeep Kumar (Moderna), Andrew Buchanan (AstraZeneca), Norbert Furtmann (Sanofi), Victor Greiff(University of Oslo) and Leonard Wossnig (LabGenius) discuss best practices for each stage of the ML process to enhance data quality and reproducibility, and improve overall progress. Learn: - How to implement best practices for data generation and collection.  - Ways of processing data to get the best ML predictions. - How to rigorously evaluate ML models.  👉 https://lnkd.in/d7kaahDp

Attending the Antibody Engineering & Therapeutics Europe conference in London next week? Be sure to catch Leonard Wossnig, CTO, on Tuesday 4th June at 3.05pm! The talk will cover the emergence of ML-enabled technology platforms that aim to enhance molecule performance, and how success hinges on a purpose-built tech stack that puts data quality first. Learn how the deep integration of predictive assays, data generation, data capturing, and data-pre-processing are all needed to enable iterative active learning for lead optimisation of multispecifics. If you'd like to meet with Leonard in London please get in touch at partnerships@labgeni.us To register visit: https://lnkd.in/g7cRV49 #drugdiscovery #antibody #machinelearning #multispecifics

In business news, LabGenius, a drug discovery company pioneering the use of machine learning for the discovery of novel therapeutic antibodies, announced that it has closed a £35 million Series B financing round. The investment brings LabGenius’ total funding to date to £58 million. LabGenius will use the capital raised to expand the scope of its ML-driven discovery platform and progress a wholly-owned pipeline of multispecific antibodies towards the clinic. Building on the success of a recent research collaboration with Sanofi, the extended platform capability will facilitate broader strategic partnerships across multiple therapeutic modalities.  https://lnkd.in/erQrPsTE

I had a wonderful time at PEGS Boston this week, both seeing the incredible progress of others and presenting on our own work at LabGenius. I highlighted our work using active learning to optimise TCEs for selective killing of tumour vs. healthy cells both in our case study with HER2 and one of our internal programs. Excited to see all the progress next year!

Coming to the end of a fantastic 48 hrs in the Bay Area. Highlights were: (1) Representing LabGenius on SynBioBeta's AI for protein design panel alongside rockstars Kathy Y. Wei, Ph.D. (310.ai), Elise de Reus (Cradle) and Maya Skubatch (Wilson Sonsini Goodrich & Rosati) (2) Catching up with Genentech's Maria Bagniewska, PhD, Gilead Sciences's Samuel Kitara and Briefly Bio's Staffan Piledahl. (3) Filming the next instalment of 'LabGenius The Movie' 📽 with the legendary MC Hammer!! https://lnkd.in/e4h3rfkm

Recently, we announced that together with Valence Labs, we’re expanding our footprint to London. To make the announcement, we held a #techbio mixer at the new office in King's Cross, including a panel with some key members of the ecosystem: Julia Fan Li, Co-Founder, CEO, Micrographia Bio; Laksh Aithani: Co-Founder, CEO, CHARM Therapeutics; James Field: Co-Founder, CEO, LabGenius; moderated by our own Chris Gibson! We're looking forward to the office officially opening next month! Have a look at the teaser video below, or watch the full panel here: https://lnkd.in/gTJHfs3u

🚀 📖 Thrilled to share our team's paper published in mAbs exploring the use of VHH domains in multispecific antibody discovery and development, and the role of machine learning in accelerating this. 💡 LabGenius' Michael Mullin, James McClory, Winston Haynes, Justin J. Grace, Nathan Robertson and Gino Van Heeke discuss: - The potential of camelid-derived VHH antibodies as modular building blocks for therapeutics, including immune cell engagers. - Insights into the engineering and application of VHHs in multispecific antibody formats. - How machine learning can improve lead discovery and optimisation of VHH multispecifics. - Current preclinical and clinical stage VHH-based multispecific molecules. 👉 Read the paper here: https://lnkd.in/eFJ6ePEV #antibody #multispecific #VHH #drugdiscovery #therapeutic

My incredible EA and friend Louise Clark is embarking on her next adventure! Over the past 5 years, I've learned so much from working with Louise and have seen the incredible impact that a talented EA can have across an entire organisation. I'm now kicking off the search for Louise's successor (big shoes to fill) so please do share widely! https://lnkd.in/g2hdRXYR